Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
Key takeaways
Artificial intelligence (AI) offers major opportunities to improve health care, however, current use is fragmented.
To facilitate the uptake of AI in cardiovascular care, the European Cardiovascular Health...
Key takeaways
Artificial intelligence (AI) offers major opportunities to improve health care, however, current use is fragmented.
To facilitate the uptake of AI in cardiovascular care, the European Cardiovascular Health...
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App.
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App.
NEW BRITAIN, Pa. — THROMBOLEX, Inc., a leader in the development of innovative treatments for pulmonary embolism (PE), announced the interim analysis of the first 150 patients in RAPID-PE, a prospective, multicenter, single-arm study of...
NEW BRITAIN, Pa. — THROMBOLEX, Inc., a leader in the development of innovative treatments for pulmonary embolism (PE), announced the interim analysis of the first 150 patients in RAPID-PE, a prospective, multicenter, single-arm study of...
The company’s technologies include the ALTO® Abdominal Stent Graft System, the AFX®2 Endovascular AAA System, the DETOUR® System for percutaneous bypass in PAD, and the Pounce™ Thrombectomy System.
The company’s technologies include the ALTO® Abdominal Stent Graft System, the AFX®2 Endovascular AAA System, the DETOUR® System for percutaneous bypass in PAD, and the Pounce™ Thrombectomy System.
The new codes, 37X47 and 37X48, describe percutaneous transcatheter renal sympathetic denervation procedures and are expected to become effective January 1, 2028.
The new codes, 37X47 and 37X48, describe percutaneous transcatheter renal sympathetic denervation procedures and are expected to become effective January 1, 2028.
James Leung, MBBS; John French, MBChB, PhD; James Xu, MBBS, PhD; Kathryn Wales, MD; Hashim Kachwalla, MBBS; Krishna Kaddapu, MBBS, PhD; Sarah Fares, MPhil; Viet Dang, MBBS; Tamer Badie, MBBS; Christian Mussap, MBBS, PhD; Rohan Rajaratnam, MBBS; Dominic Leung, MBBS, PhD; Sidney Lo, MBBS; Craig Juergens, MBBS, DMedSc
This study compared visual, robotic, and intracoronary imaging lesion length measurements performed during robotic-assisted percutaneous coronary intervention cases enrolled in the PARTY trial.
This study compared visual, robotic, and intracoronary imaging lesion length measurements performed during robotic-assisted percutaneous coronary intervention cases enrolled in the PARTY trial.
Marco Angelillis, MD; Leonardo Misuraca, MD; Paolo Calabria, MD; Cristina Giannini, MD, PhD; Paolo Spontoni, MD; Laura Stazzoni, MD; Alessandro Sticchi, MD, PhD; Giulia Costa, MD, PhD; Marco De Carlo, MD, PhD
The article describes a novel bailout technique illustrated through a clinical case, the SAFE-SEAL (Suture-Assisted Femoral Emergency SEALing) technique, designed to achieve hemostasis following failure of the plug-based component of a hybrid...
The article describes a novel bailout technique illustrated through a clinical case, the SAFE-SEAL (Suture-Assisted Femoral Emergency SEALing) technique, designed to achieve hemostasis following failure of the plug-based component of a hybrid...
A 78-year-old man was admitted with non-ST-segment elevation myocardial infarction. He had a history of ischemic heart disease with prior percutaneous coronary intervention to the right coronary artery and mid-left anterior descending artery.
A 78-year-old man was admitted with non-ST-segment elevation myocardial infarction. He had a history of ischemic heart disease with prior percutaneous coronary intervention to the right coronary artery and mid-left anterior descending artery.
Maedeh Zokaei Nikoo, MD; Rafey Feroze, MD; Luis Augusto Palma Dallan, MD, PhD; Yusef Saeed, MD; Alexander Cove, MD; Abdullah Altorbag, MD; Andreas A. Towers, MD; Syed R. Nabi, MD; Harsh Amin, MD; Sabin Lama, MD; Christopher Mishreky, MD; Kareem Fanous, MD; Justin M. Dunn, MD; Vinicius Esteves, MD; Steven J. Filby, MD
The authors investigated the association between postprocedural antithrombotic regimen and compute tomography-derived device healing following WATCHMAN FLX Pro (Boston Scientific) implantation.
The authors investigated the association between postprocedural antithrombotic regimen and compute tomography-derived device healing following WATCHMAN FLX Pro (Boston Scientific) implantation.
The authors assessed the feasibility, technical considerations, and procedural safety of totally percutaneous transfemoral transcatheter aortic valve replacement via synthetic aortobifemoral bypass grafts.
The authors assessed the feasibility, technical considerations, and procedural safety of totally percutaneous transfemoral transcatheter aortic valve replacement via synthetic aortobifemoral bypass grafts.
A 74-year-old woman with dilated cardiomyopathy, marked left ventricular enlargement, and severe functional mitral regurgitation remained in decompensated heart failure despite dobutamine therapy. Coronary angiography showed no significant...
A 74-year-old woman with dilated cardiomyopathy, marked left ventricular enlargement, and severe functional mitral regurgitation remained in decompensated heart failure despite dobutamine therapy. Coronary angiography showed no significant...
A 20-year-old woman presented with resistant hypertension despite taking 3 antihypertensives. On examination, she had a blood pressure of 180/100 mm Hg and a systolic murmur heard under the left scapula.
A 20-year-old woman presented with resistant hypertension despite taking 3 antihypertensives. On examination, she had a blood pressure of 180/100 mm Hg and a systolic murmur heard under the left scapula.
Neeraj Shah, MD, MPH; Raveen Bazaz, MD; Bassel Sayegh, MD; Mitsugu Ogawa, MD; Dennis Phillips, MD; Benjamin Kristobak, MD
An 83-year-old man with diastolic heart failure, chronic atrial fibrillation on warfarin, severe atrial-functional mitral regurgitation, and a secundum atrial septal defect in an anterior/superior location underwent transcatheter edge-to-edge...
An 83-year-old man with diastolic heart failure, chronic atrial fibrillation on warfarin, severe atrial-functional mitral regurgitation, and a secundum atrial septal defect in an anterior/superior location underwent transcatheter edge-to-edge...
